800-680-7137Call For Help With Addiction
Talk To Someone Now
- Find a Clinic Near You
- Access Help and Resources
- Get 24-Hour Guidance and Information
Sponsored| Name | Address | City |
|---|---|---|
| Community Medical Services Wasilla | 2521 Mountain Village Dr Suite F | Wasilla |
| Frontier Family Medicine | 300 W Swanson Ave | Wasilla |
| Narcotic Drug Treatment Center, Inc. | 1015 E 6th Ave | Anchorage |
| Anchorage Comprehensive Treatment Center | 3230 C Street Suite 100 | Anchorage |
No results found!
Finding MOUD Treatment in Wasilla and the Mat-Su Valley
Wasilla anchors the Matanuska-Susitna Borough, one of Alaska’s fastest-growing regions and, alongside Anchorage, one of the areas hit hardest by opioid overdoses. For years, the practical catch here was methadone.
Federal law allows methadone for opioid use disorder only through a certified opioid treatment program (OTP), so many Mat-Su residents drove into Anchorage for daily dosing. That is no longer the full picture.
Buprenorphine, including Suboxone, can now be prescribed in a regular doctor’s office and started by telehealth, and all three FDA-approved medications for opioid use disorder (MOUD) are part of what is available to people in the Valley. The listings on this page show providers you can reach, and the helpline is there when you want to talk an option through.
Your Medication Options, and Where Each One Comes From
There are three medications approved for opioid use disorder, sometimes grouped under the older label medication-assisted treatment (MAT), and they are not obtained the same way.
Methadone, a full opioid agonist that steadies withdrawal and cravings, is dispensed for opioid use disorder only at a certified opioid treatment program, not at a pharmacy.
Buprenorphine, including the buprenorphine-naloxone combinations sold as Suboxone and the extended-release monthly injection Sublocade, can be prescribed in an office-based setting by any clinician with a standard DEA registration and filled at a pharmacy, or provided through an OTP.
Naltrexone, including the monthly Vivitrol injection, is not a controlled substance and can be prescribed by any licensed provider, though a person has to be off opioids for a set stretch first so the injection does not trigger withdrawal.
Those two settings, the opioid treatment program and office-based opioid treatment (OBOT), are what the listings below represent. If you want to understand how methadone and Suboxone compare before you call, or read more about what methadone treatment involves, start there.
The right medication is a decision you make with a clinician, and no one option is best for everyone.
Take-Home Doses and Telehealth Across the Valley’s Distances
Distance is the defining barrier in the Mat-Su, and the current rules are built to shrink it. Under the 2024 update to the federal OTP regulations, patients who are stable in treatment can receive take-home methadone, up to a 28-day supply, on a schedule the program sets based on how treatment is going, rather than showing up every day.
Those same rules allow treatment to begin by telehealth and authorized mobile medication units that can bring dosing closer to where people live. Buprenorphine goes further. As of 2026, it can be started through telehealth, including by phone in many cases, without a prior in-person visit.
Those telehealth rules run through the end of 2026 and are still being finalized, so confirm what is current with a provider. Alaska is putting money behind this through the state’s Positive Pathways for Alaska Recovery grant program, which funds tele-MOUD, mobile methadone units, and flexible dosing specifically to reduce geographic barriers.
If you are already in treatment and moving or transferring, ask a program about guest dosing and about continuing long-term methadone treatment without a gap.
Starting Treatment, and What the First Days Look Like
Most programs begin with an intake assessment that covers your opioid use, health history, and what you are hoping treatment will do. Bring an ID and insurance information if you have them, but not having those should not stop you from calling.
However, since today’s drug supply in the Mat-Su is dominated by fentanyl, starting buprenorphine too soon after using can set off sudden, severe withdrawal, known as precipitated withdrawal. This means the timing of a first dose matters, and there are approaches clinicians use to manage it.
If you are weighing starting methadone when fentanyl is involved, that is a conversation to have directly with a program. Some providers offer same-day or walk-in starts and some can begin with a telehealth visit; availability varies, so ask when you call.
Paying for Treatment in Alaska
Cost is often the first worry, so start here. Alaska Medicaid covers all three medications for opioid use disorder, and the state delivers much of its substance use treatment through an 1115 Behavioral Health Medicaid waiver that funds opioid treatment services across a broader network of providers.
Private insurance is federally required to cover substance use and mental health treatment, and Medicare covers MOUD as well. For people without coverage, many programs accept self-pay and some offer sliding-scale fees, and federal SAMHSA block grant funds help support treatment for those who cannot pay.
When you call a provider on this page, asking what they accept and whether they can help you enroll in Medicaid is a reasonable first question.
The Overdose Picture in the Mat-Su Borough
The Mat-Su has carried a heavy share of Alaska’s opioid burden. State epidemiologists reported that the Mat-Su and Anchorage regions had the highest rates of nonfatal opioid overdoses in Alaska from 2019 through 2024, and an analysis of CDC data put the borough’s 2024 overdose death rate near 51 per 100,000.
Statewide, fentanyl was involved in about 73% of overdose deaths in 2024, and it is frequently mixed with methamphetamine or other substances. There is a real note of progress in the same data.
Overdose deaths declined in 2024 after a record year in 2023. If you want to understand how opioid use disorder takes hold, that context helps, and the practical takeaway is that effective medication treatment exists close to home and a first call is a concrete step.
Care for Specific Situations
Some people come to treatment carrying an added layer of worry, and a few situations are worth naming here. American Indian and Alaska Native residents have been affected by overdose at disproportionately high rates in Alaska, and tribal health organizations, including the Alaska Native Tribal Health Consortium, are part of the treatment and naloxone network in the region.
During pregnancy, medication treatment with methadone or buprenorphine is the recommended standard of care, and it protects both mother and baby. Although fear of child-welfare involvement keeps some people from seeking help, it is worth knowing that staying in treatment is what clinicians and Alaska’s Plan of Safe Care approach are designed to support.
You can read more about methadone during pregnancy if that applies to you. People entering treatment through a therapeutic court, probation, or reentry after incarceration can ask a program directly whether it accepts their referral and can document attendance.
Naloxone and Overdose Safety
Anyone close to opioid use in the Valley should keep naloxone on hand. In Alaska, the medication that reverses an opioid overdose is available free through Project HOPE, the state’s distribution program, which supplies it under a statewide medical standing order – Alaska Statute 17.20.085.
Local overdose response programs distribute the supplies. Statewide, that has amounted to about 45,000 kits in 2024. An over-the-counter version of Narcan is also sold in pharmacies. Alaska’s Good Samaritan law protects someone who calls 911 during an overdose from arrest or prosecution for drug possession, so calling for help is the right move.
A return to use can happen and is a manageable part of treating a chronic condition, not a failure; knowing how to recognize and respond to an opioid overdose keeps people alive while treatment continues.
Questions People in Wasilla Ask
Do I have to go to a clinic every day for methadone?
Not indefinitely. Daily dosing is common early in treatment, but under the 2024 federal rules, stable patients can earn take-home doses, up to a 28-day supply, on a schedule the program sets. For someone driving in from the Mat-Su, that flexibility is a large part of what makes treatment sustainable.
Can I start treatment without going into Anchorage?
Often, yes, for buprenorphine. As of 2026, buprenorphine can be started by telehealth, including by phone in many cases, without a prior in-person visit. Methadone for opioid use disorder is still dispensed through an opioid treatment program, though some programs can begin the process with a telehealth visit. Confirm current options with a provider.
Which is better, methadone or Suboxone?
Neither is better for everyone. Research finds methadone and buprenorphine similarly effective at reducing opioid use, and the right choice depends on your history, the fentanyl in the local supply, how much structure helps you, and what you and a clinician decide together.
Will Alaska Medicaid pay for it?
Alaska Medicaid covers all three medications for opioid use disorder. Many Mat-Su providers accept Medicaid, and some can help you enroll. Private insurance and Medicare also cover MOUD, and self-pay or sliding-scale options exist at some programs.
Is being on medication long-term just trading one drug for another?
No, methadone and buprenorphine, taken as prescribed, stabilize the brain without the cycle of intoxication and withdrawal, which is why long-term medication is considered legitimate, effective care rather than a temporary step to get past. How long to stay on medication is a decision made with your clinician. You can explore common questions about methadone treatment for more.
About This Page
Last reviewed July 2026.
Sources:
- Alaska Department of Health, 2024 Drug Overdose Mortality Update (2025): https://health.alaska.gov/media/wqql4fhp/2024-drug-overdose-mortality-update.pdf
- Alaska Department of Health, Epidemiology Bulletin No. 5, Nonfatal Opioid Overdoses, Alaska 2019 to 2024 (2025): https://epi.alaska.gov/bulletins/docs/b2025_05.pdf
- Alaska Department of Health, Project HOPE: Get Naloxone: https://health.alaska.gov/en/services/project-hope-get-naloxone/
- Alaska Department of Health, Opioids Prevention and Recovery (Good Samaritan law): https://health.alaska.gov/en/education/drugs-and-alcohol/opioids-prevention-and-recovery/
- Alaska Department of Health, 1115 Behavioral Health Medicaid: https://health.alaska.gov/en/services/1115-behavioral-health-medicaid/
- Alaska Division of Behavioral Health, Positive Pathways for Alaska Recovery grant program (FY2026 to FY2027): https://aws.state.ak.us/OnlinePublicNotices/Notices/Attachment.aspx?id=158290
- SAMHSA and DEA, Final Telemedicine Rule for Buprenorphine Access (2025 to 2026): https://www.samhsa.gov/about/news-announcements/statements/2025/dea-and-hhs-issue-final-telemedicine-rule-for-buprenorphine-access
- Federal Register, Fourth Temporary Extension of Telemedicine Flexibilities (effective through December 31, 2026): https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled
Methadone Centers is an informational directory and referral service. It is not a medical provider or treatment facility and does not provide medical advice. Decisions about medication and treatment should be made with a licensed clinician.
Some listings and the helpline on this site are sponsored. Calls to the general helpline may be routed to SAMHSA or to a verified treatment provider. Methadone Centers does not receive a commission based on which provider a caller chooses, and there is no obligation to enter treatment.
Last Updated: July 27, 2026